Literature DB >> 20521871

Prevalence of fecal carriage of antibiotic-resistant bacteria in patients with acute surgical abdominal infections.

Abbas Chabok1, Maria Tärnberg, Kenneth Smedh, Lars Påhlman, Lennart E Nilsson, Christian Lindberg, Håkan Hanberger.   

Abstract

OBJECTIVE: Antibiotic resistance is increasing worldwide. The aims of the current study were to determine the fecal carriage of antibiotic-resistant bacteria and antibiotic treatment in surgical patients admitted to hospital due to acute intra-abdominal infections.
MATERIALS AND METHODS: Eight Swedish surgical units participated in this prospective multicenter investigation. Rectal swabs were obtained on admission to hospital. Cultures were performed on chromogenic agar and antibiotic susceptibility testing was performed using the disk diffusion method. Extended-spectrum beta-lactamase (ESBL)-phenotype was confirmed by Etest.
RESULTS: Rectal samples were obtained and analyzed from 208 patients with intra-abdominal surgical infections. Surgery was performed in 134 patients (65%). Cephalosporins were the most frequently used empirical antibiotic therapy. The highest rates of resistance among Enterobacteriaceae were detected for ampicillin (54%), tetracycline (26%), cefuroxime (26%) and trimethoprim-sulfamethoxazole (20%). The prevalence of decreased susceptibility (I + R) for the other antibiotics tested was for ciprofloxacin 20%, piperacillin-tazobactam 17%, cefotaxime 14%, ertapenem 12%, gentamicin 3% and imipenem 0%. ESBL-producing Enterobacteriaceae were found in samples from 10 patients (5%). Three patients had five E. coli isolates producing AmpC enzymes.
CONCLUSIONS: This study shows a high rate of resistance among Enterobacteriaceae against antibiotics which are commonly used in Sweden and should have implications for the future choice of antibiotics for surgical patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20521871     DOI: 10.3109/00365521.2010.495417

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Effective photodynamic therapy against microbial populations in human deep tissue abscess aspirates.

Authors:  Constantine G Haidaris; Thomas H Foster; David L Waldman; Edward J Mathes; Joanne McNamara; Timothy Curran
Journal:  Lasers Surg Med       Date:  2013-08-29       Impact factor: 4.025

2.  Short-term Intravenous Antibiotic Treatment in Uncomplicated Diverticulitis Does Not Increase the Risk of Recurrence Compared to Long-term Treatment.

Authors:  Cosimo Riccardo Scarpa; Nicolas Christian Buchs; Antoine Poncet; Béatrice Konrad-Mugnier; Pascal Gervaz; Philippe Morel; Frédéric Ris
Journal:  Ann Coloproctol       Date:  2015-04-30

3.  Outpatient antibiotic use and the incidence of acute appendicitis in Finland: a nationwide study from 1990-2008.

Authors:  Imre Ilves; Pekka Miettinen; Pentti Huovinen; Karl H Herzig; Jennyl Alajääski; Paulina Salminen; Hannu Paajanen
Journal:  Surg Infect (Larchmt)       Date:  2013-07-16       Impact factor: 2.150

Review 4.  Antibiotics for uncomplicated diverticulitis.

Authors:  Marie-Louise Dichman; Steffen Jais Rosenstock; Daniel M Shabanzadeh
Journal:  Cochrane Database Syst Rev       Date:  2022-06-22

Review 5.  Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis.

Authors:  Yihienew M Bezabih; Alemayehu Bezabih; Michel Dion; Eric Batard; Samson Teka; Abiy Obole; Noah Dessalegn; Alelegn Enyew; Anna Roujeinikova; Endalkachew Alamneh; Corinne Mirkazemi; Gregory M Peterson; Woldesellassie M Bezabhe
Journal:  JAC Antimicrob Resist       Date:  2022-06-02

6.  The prevalence of ESBL-producing Enterobacteriaceae in a nursing home setting compared with elderly living at home: a cross-sectional comparison.

Authors:  Andreas Blom; Jonas Ahl; Fredrik Månsson; Fredrik Resman; Johan Tham
Journal:  BMC Infect Dis       Date:  2016-03-04       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.